Lenvaxen 4 MG And 10 MG (Lenvatinib)

Basic Product Information of Lenvaxen (Lenvatinib) 4mg and 10mg

How Lenvaxen (Lenvatinib) Works

Lenvaxen contains Lenvatinib, an oral multi-targeted receptor tyrosine kinase inhibitor with potent antiangiogenic properties. Lenvatinib inhibits the kinase activity of VEGFR-1, -2, and -3, FGFR-1, -2, -3, and -4, PDGFR-alpha, KIT (CD117), and RET, receptors involved in tumour angiogenesis (the formation of new blood vessels that feed a tumour), tumour growth, and cancer progression.

By blocking VEGF- and FGF-driven angiogenesis alongside KIT-dependent signalling and RET-fusion or RET-mutant driven tumour growth, Lenvaxen cuts off the blood supply tumours depend on while directly inhibiting proliferation of malignant cells. This broad, multi-pathway mechanism has shown activity across several difficult-to-treat solid tumour types, including thyroid, liver, kidney, and endometrial cancers.

Lenvaxen is taken as a once-daily oral capsule, used as monotherapy in thyroid and liver cancer, and in combination with other agents such as everolimus or pembrolizumab in kidney and endometrial cancer, depending on the specific indication and treatment line.

Indications for Lenvaxen (Lenvatinib)

Lenvaxen (Lenvatinib) is indicated for the following conditions:

Benefits of Lenvaxen (Lenvatinib) 4mg and 10mg

How to Take Lenvaxen (Lenvatinib)

Monitoring and Dosage Adjustments

Regular monitoring is essential throughout Lenvaxen treatment. Your oncologist will monitor blood pressure, checked weekly during the first two months and periodically thereafter, liver function tests, renal function and urine protein, thyroid-stimulating hormone (TSH) levels, and cardiac function in patients with cardiac risk factors. Monitoring also includes serum calcium and periodic ECG where indicated. Report any severe headache, chest pain, breathlessness, severe abdominal pain, unusual bleeding, swelling, or signs of infection to your doctor immediately.

Drug Interactions and Important Information

Use with caution alongside other medicines known to prolong the QTc interval, and inform your physician of any history of hypertension, cardiac disease, or thyroid disorders before starting treatment. When Lenvaxen is used in combination with everolimus or pembrolizumab, refer also to the prescribing information for those medicines, as combination regimens carry their own additional monitoring requirements.

Surgery or invasive procedures should be planned around Lenvaxen treatment, as it may impair wound healing; treatment is typically interrupted before elective surgery. Women of childbearing potential should use effective contraception during treatment and for at least 30 days after the final dose. Always inform your physician of all medications, supplements, and herbal products you are currently taking before starting Lenvaxen.

Side Effects and Precautions

Who Should Use Lenvaxen (Lenvatinib)?

Lenvaxen is suitable for adult patients diagnosed with radioactive iodine-refractory, locally recurrent or metastatic differentiated thyroid cancer, unresectable hepatocellular carcinoma requiring first-line therapy, advanced renal cell carcinoma requiring combination therapy, or advanced endometrial carcinoma that has progressed on prior systemic therapy. It is prescribed by medical oncologists experienced in managing multikinase inhibitor therapy and its associated cardiovascular, renal, and hepatic risks. A thorough medical assessment including blood pressure, cardiac evaluation, liver and thyroid function, and urine protein is required before initiating treatment.

Manufacturer: Everest Pharmaceuticals Ltd.

Everest Pharmaceuticals Ltd. is a vertically integrated pharmaceutical company based in Dhaka, Bangladesh, focused on complex, technology-driven specialty medicines across oncology, nephrology, and virology. Operating under Bangladesh’s TRIPS/Doha Declaration exemption for least-developed countries, Everest manufactures advanced generics such as Lenvaxen under cGMP-compliant standards, with the stated mission of making high-cost, life-saving medicines accessible and affordable to patients around the world. Lenvaxen is one of Everest’s specialty oncology products, offering a bioequivalent alternative to Lenvima by Eisai and Merck at a fraction of the cost.

Global Supplier: Mediaid Pharmacy with Worldwide Shipping

Mediaid Pharmacy is a trusted global supplier of specialty and oncology medications. We ensure Lenvaxen (Lenvatinib) is accessible to patients and healthcare providers worldwide through reliable worldwide shipping. Whether you are located in South Asia, the Middle East, Africa, Europe, or beyond, Mediaid Pharmacy provides fast and reliable delivery with full order support. Contact us directly via WhatsApp, phone, or WeChat for pricing, availability, and delivery enquiries.

Why Choose Lenvaxen (Lenvatinib) from Mediaid Pharmacy?

Lenvaxen represents a well-established, versatile option across four distinct cancer types. As the generic equivalent of Lenvima by Eisai and Merck, it delivers the same active ingredient, Lenvatinib, with the same proven multi-target receptor tyrosine kinase inhibition mechanism at a dramatically more affordable price. Manufactured by Everest Pharmaceuticals Ltd. under cGMP-compliant standards and distributed globally by Mediaid Pharmacy, Lenvaxen gives patients worldwide access to advanced targeted cancer therapy without the financial burden of brand-name alternatives. For patients and physicians seeking a proven, affordable, and accessible Lenvatinib option with worldwide delivery, Lenvaxen from Mediaid Pharmacy is the trusted choice.

Frequently Asked Questions About Lenvaxen (Lenvatinib)